Author:
Miellet Willem R.,Mariman Rob,Pluister Gerlinde,de Jong Lieke J.,Grift Ivo,Wijkstra Stijn,van Logchem Elske M.,van Veldhuizen Janieke,Immink Marie-Monique,Wijmenga-Monsuur Alienke J.,Rots Nynke Y.,Sanders Elisabeth A. M.,Bosch Thijs,Trzciński Krzysztof
Abstract
AbstractCarriage of Neisseria meningitidis is an accepted endpoint in monitoring meningococcal vaccines effects. We have assessed N. meningitidis and vaccine-type genogroup carriage prevalence in college students at the time of MenACWY vaccine introduction in the Netherlands, and evaluated the feasibility of saliva sampling for the surveillance of carriage. For this, paired saliva and oropharyngeal samples collected from 299 students were cultured for meningococcus. The DNA extracted from all bacterial growth was subjected to qPCRs quantifying meningococcal and genogroup-specific genes presence. Samples negative by culture yet positive for qPCR were cultured again for meningococcus. Altogether 74 (25%) of students were identified as meningococcal carrier by any method. Sixty-one students (20%) were identified as carriers with qPCR. The difference between number of qPCR-positive oropharyngeal (n = 59) and saliva (n = 52) samples was not significant (McNemar’s test, p = 0.07). Meningococci were cultured from 72 students (24%), with a significantly higher (p < 0.001) number of oropharyngeal (n = 70) compared with saliva (n = 54) samples. The prevalence of genogroups A, B, C, W, and Y was none, 9%, 1%, 1% and 6%, respectively, and 8% of students carried MenACWY vaccine-type genogroup meningococci. Saliva is easy to collect and when combined with qPCR detection can be considered for meningococcal carriage studies.
Funder
the National Institute for Public Health and the Environment
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Jafri, R. Z. et al. Global epidemiology of invasive meningococcal disease. Popul. Health Metr. 11(1), 17 (2013).
2. Christensen, H., May, M., Bowen, L., Hickman, M. & Trotter, C. L. Meningococcal carriage by age: A systematic review and meta-analysis. Lancet Infect. Dis. 10(12), 853–861 (2010).
3. Knol, M. J., Ruijs, W. L., Antonise-Kamp, L., de Melker, H. E. & van der Ende, A. Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018. Euro Surveill. 23(16), 18–00158 (2018).
4. Schurink-van 't Klooster, T. M. & de Melker, H. E. The National Immunisation Programme in the Netherlands: Surveillance and developments in 2018–2019 (Rijksinstituut voor Volksgezondheid en Milieu RIVM, 2019).
5. Maiden, M. C. J. et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis. 197(5), 737–743 (2008).